KIT and gastrointestinal stromal tumor: Mutually exclusive <i>KIT</i> and <i>PDGFRA</i> mutations are central events in GIST pathogenesis, and their understanding is crucial because specific treatment targeting oncogenic KIT and PDGFRA activation (especially imatinib) has become available.